Search research articles
Contact Us
Filters
Showing results (71-80 of 86) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2001
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B
D M Savarese, S Halabi, V Hars, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2001
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer
Y J Ko, E J Small, F Kabbinavar, et al.
The Journal of Urology
|
November 1, 1996
Radiotherapy for high grade clinically localized adenocarcinoma of the prostate
M Roach, S Meehan, S Kroll, et al.
Cancer Research
|
April 6, 2001
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study
R A Bok, S Halabi, D T Fei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 15, 2008
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
J E Rosenberg, S Halabi, B L Sanford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2000
Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
E J Small, M Meyer, M E Marshall, et al.
Cancer Research
|
July 1, 1996
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping
M L Cher, G S Bova, D H Moore, et al.
The Journal of Urology
|
May 1, 1997
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade
P F Schellhammer, P Venner, G P Haas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 28, 2019
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
E J Small, F Saad, S Chowdhury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 3, 2001
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
W K Kelly, T Curley, S Slovin, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 86) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2001
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B
D M Savarese, S Halabi, V Hars, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2001
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer
Y J Ko, E J Small, F Kabbinavar, et al.
The Journal of Urology
|
November 1, 1996
Radiotherapy for high grade clinically localized adenocarcinoma of the prostate
M Roach, S Meehan, S Kroll, et al.
Cancer Research
|
April 6, 2001
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study
R A Bok, S Halabi, D T Fei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 15, 2008
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
J E Rosenberg, S Halabi, B L Sanford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2000
Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
E J Small, M Meyer, M E Marshall, et al.
Cancer Research
|
July 1, 1996
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping
M L Cher, G S Bova, D H Moore, et al.
The Journal of Urology
|
May 1, 1997
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade
P F Schellhammer, P Venner, G P Haas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 28, 2019
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
E J Small, F Saad, S Chowdhury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 3, 2001
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
W K Kelly, T Curley, S Slovin, et al.
Page
of 9